Lumiris

In the expansive market of fertility treatment, Lumiris Spectral Solutions S.L. stands out as a technology-driven company, committed to revolutionizing the way IVF specialists evaluate embryos at the clinic. At the core of our mission lies a profound desire to alleviate the pain endured by patients dealing with unsuccessful IVF cycles. We understand the emotional toll of fertility struggles and are dedicated to empowering both clinicians and patients with the tools that will assist in the crucial moment of embryo selection to dramatically reduce the time to get pregnant.

In response to the pressing need for more accurate embryo evaluation methods, Lumiris Spectral Solutions S.L. has developed a groundbreaking medical device based on hyperspectral imaging and AI analysis to observe the metabolism of live embryos in real-time in a safe and non-invasive way. Our diagnostic system promises to redefine the standards of care in the fertility market by providing IVF specialists with a comprehensive and unbiased assessment of embryo quality, enabling them to make informed decisions before embryo transfer.

The development of Lumiris technology started 5 years ago at the Institute of Bioengineering of Catalonia (IBEC) thanks to the support of a VC who invested €1.5M in the IBEC research group to develop technologies to improve women’s health. With this strong kick-off, we managed to expand our financial support with public non-dilutive grants up to a total €3M. The Lumiris project became an IBEC spin-off in January 2024 when our path to the clinic and market was mature enough.

We have designed a prototype of the medical device for which we got a patent PCT clear, and we are now entering national phases, providing robust protection for both our device and method. In addition to our patent protection, Lumiris Spectral Solutions S.L. has forged strategic partnerships with key industry players. Among these partnerships, our collaboration with M-Squared, a renowned laser and microscope manufacturing partner known for its excellence in precision engineering, ensures the production of high-quality devices. Furthermore, our partnership with Dexeus, a leading clinic in reproductive medicine, provides us with invaluable clinical insights and validation.

Lumiris team has made significant scientific breakthroughs that have earned us widespread recognition within the medical community. Our preclinical work published in PNAS has achieved unprecedented classification of mouse embryos with different metabolic profiles, which are indistinguishable with the gold standard technology in the market. Our work with oocytes has yielded invaluable insights into age-related fertility decline by discriminating between oocytes based on their age-related viability. We have also developed a predictive model capable of identifying which oocytes are most likely to develop into blastocysts—a critical step in the IVF process.

Our research endeavors with human embryos have unveiled the vast and diverse array of metabolic profiles present, surpassing traditional morphological assessments. This deeper understanding of metabolic dynamics will provide IVF specialists with invaluable insights into embryo health and viability, paving the way for more personalized and effective fertility treatments.

At Lumiris Spectral Solutions S.L., we are guided by a set of core values that serve as the foundation of our company. Scientific rigor forms the bedrock of our approach, as we adhere to the highest standards of excellence in research and development. Embryo safety is paramount, and ensure that our product will meet stringent regulatory requirements. Empathy with patients warrants that we understand the emotional toll of infertility struggles, as we strive to reduce waiting times for patients to achieve a pregnancy. We believe in the power of technology to drive positive change in society, and we are dedicated to advancing knowledge transfer and innovation within the IVF industry.

Our target market encompasses IVF clinics seeking to elevate their services by incorporating science-based decision-making into the embryo selection process. With a target market size of €1.8 billion and a projected CAGR of 10%, there is ample opportunity for growth and expansion within the fertility market. Lumiris Spectral Solutions S.L. is poised to lead the way in transforming the landscape of reproductive healthcare, offering hope to individuals and families around the world.